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Abstract
Background: The current disease model for leishmaniasis suggests that only a proportion of infected individuals develop
clinical disease, while others are asymptomatically infected due to immune control of infection. The factors that determine
whether individuals progress to clinical disease following Leishmania infection are unclear, although previous studies
suggest a role for host genetics. Our hypothesis was that canine leishmaniasis is a complex disease with multiple loci
responsible for the progression of the disease from Leishmania infection.
Methodology/Principal Findings: Genome-wide association and genomic selection approaches were applied to a
population-based case-control dataset of 219 dogs from a single breed (Boxer) genotyped for ,170,000 SNPs. Firstly, we
aimed to identify individual disease loci; secondly, we quantified the genetic component of the observed phenotypic
variance; and thirdly, we tested whether genome-wide SNP data could accurately predict the disease.
Conclusions/Significance: We estimated that a substantial proportion of the genome is affecting the trait and that its
heritability could be as high as 60%. Using the genome-wide association approach, the strongest associations were on
chromosomes 1, 4 and 20, although none of these were statistically significant at a genome-wide level and after correcting
for genetic stratification and lifestyle. Amongst these associations, chromosome 4: 61.2–76.9 Mb maps to a locus that has
previously been associated with host susceptibility to human and murine leishmaniasis, and genomic selection estimated
markers in this region to have the greatest effect on the phenotype. We therefore propose these regions as candidates for
replication studies. An important finding of this study was the significant predictive value from using the genomic
information. We found that the phenotype could be predicted with an accuracy of ,0.29 in new samples and that the
affection status was correctly predicted in 60% of dogs, significantly higher than expected by chance, and with satisfactory
sensitivity-specificity values (AUC=0.63).
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Introduction
Leishmaniasis is a vector-borne disease affecting humans and
animals, caused by parasitic species of the genera Leishmania and
transmitted by the bite of phlebotomine sand flies. Around the
Mediterranean basin, visceral (VL) and cutaneous (CL) human
leishmaniasis as well as canine leishmaniasis (CanL) are caused by
Leishmania infantum. The current disease model for leishmaniasis
suggests that infected individuals may live without progression
towards clinical disease manifestation probably due to immune
control of the infection.
The factors that determine whether individuals progress to
clinical disease following Leishmania infection are unclear, but
previous studies suggest a large contribution of the host genetic
background, as reviewed elsewhere [1,2]. Studies in mice [1]
provided early support for a strong genetic component to
susceptibility to Leishmania infection. In humans, most epidemio-
logical studies [3,4,5,6], candidate gene studies [7,8,9,10,11,12]
and genome-wide approaches [7,13,14] have offered further
support for genetic susceptibility to leishmaniasis, however they
did not specifically dissect the genetic factors that cause
progression of the disease following infection. Some studies have
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35349investigated genetic differences between healthy infected and
symptomatic individuals, but most of these were either not aimed
to identify candidate loci [15,16] or targeted at few candidate
genes [17,10,18]. Only Jeronimo et al. [19] have studied
progression of leishmaniasis following infection using a genome-
wide linkage approach in humans based on a few hundred
microsatellite markers. In dogs, genetic susceptibility to progres-
sion of disease from Leishmania infection is supported by the fact
that the percentage of infected dogs in endemic areas is as high as
60% [20] whereas rates of clinical CanL are much lower in these
areas [21,22]. Similarly to familial aggregation and ethnic
differences of leishmaniasis prevalence seen in humans, dog
breeds show variable susceptibility to CanL. Some breeds such as
Boxer, German shepherd and Rottweiler [23,24,25] appear more
predisposed to overt CanL. In contrast, the Ibizan hound, a dog
breed believed to have been relatively isolated in an endemic area
such as Ibiza (Balearic Islands, Spain), is reported to be resistant to
CanL [26].
Understanding the genomic factors controlling progression to
clinical disease in dogs is critical since the dog is the main natural
reservoir of Leishmania infantum infection for humans, and CanL is a
disease of great importance in veterinary medicine because of its
severity in the dog. Despite the importance of leishmaniasis in
dogs, there have been very few genetic studies of this species and
these have focused on a few candidate genes [27,25,28,29,30],
which have confirmed some genes previously found in mice and
humans. There have been no previous genome-wide studies of
genetic susceptibility to visceral leishmaniasis in the dog.
The dog has been previously proposed as a comparative animal
genetic model for disease mapping. For complex diseases, a
strategy with a first genome-wide scan genotyping tens of
thousands of single-nucleotide polymorphisms (SNPs) for a few
hundreds of dogs from one or few breeds has been suggested
[31,32,33] based on calculations of statistical power. This
approach has been based on simulation studies. For complex
phenotypes, these simulation studies demonstrate that 100–300
cases and 100–300 controls provide adequate power to detect
alleles conferring 2 to 5-fold multiplicative risk [33]. As a proof of
principle, the efficacy of the proposed design has recently been
demonstrated on several different studies [34,35,36,37,38,39,
40,41,42,43,44,45]. Moreover, Daetwyler and collaborators [46]
showed that the predictive accuracy depends upon the genomic
structure of the species, and this is favorable for canine studies
because of its low effective population increases the power in
genomic selection techniques [47].
The aim of this work was therefore to carry out a genome-wide
study of the genetic contribution to the progression of clinical
CanL from Leishmania infection. Our working hypothesis were: (i)
that the observed phenotypic variance in the progression of
leishmaniasis in infected dogs is partly explained by the genetics of
the host; (ii) that CanL is a complex disease with multiple loci
involved and an environmental component; and (iii) that genomic
information may be used to predict the progression of the disease.
We applied both genome-wide association study (GWAS) and
genomic selection approaches to a population-based case-control
dataset of 219 dogs from a single dog breed (Boxer) genotyped for
,170,000 single-nucleotide polymorphisms (SNPs) in order to
study host genetic susceptibility to progression of clinical
leishmaniasis from Leishmania infection. Firstly, we tried to identify
loci in the canine genome associated with the disease progression
phenotype. Secondly, we investigated the genetic component of
the observed phenotypic variance. Thirdly, we examined whether
genome-wide SNP data could be used to predict accurately the
phenotype.
Results
Genome-wide scan of loci affecting disease progression
A GWAS analysis testing markers individually was performed in
order to find loci associated with the progression to clinical CanL
from Leishmania infection, using a dataset of 115 healthy infected
and 104 affected Boxer dogs. All dogs had genotypes for 126,607
SNPs distributed across the genome.
Three statistical models were applied by fitting additional
covariates in order to correct for the two confounding effects
considered (described in Materials and Methods). When no
covariates were included (Model 1), the strongest associations were
found on Canis familiaris chromosomes (CFA) 1:39,058,553 bp
(Praw=1.0610
25,P genome=0.21), CFA 4: 68,238,371 bp
(Praw=1.1610
25,P genome=0.22) and CFA 20: 30,132,329 bp
(Praw=2.5610
25,P genome=0.43) (Figure S1 and Table S1).
Although healthy infected and affected samples generally clustered
together in the MDS plot (Figure S2), genetic stratification was
observed in our cleaned dataset based on the genomic inflation
factor (l=1.29), with C1 capturing twice the stratification
captured by C2. The associations on CFA1 and 4 remained
when confounding effects were accounted for although signifi-
cance did not reach the genome-wide level (Table S1). Genetic
stratification, corrected by fitting the two first dimensions from the
multidimensional scaling analysis (C1 and C2), is likely to explain
part of the initial association in Model 1, as Praw values for the ten
strongest associated SNPs on CFA 1 and 4 were an order of
magnitude higher when stratification was accounted for (Model 2).
Nevertheless, associations of C1 and C2 with each of these
markers were not significant (data not shown). Inclusion of dog
lifestyle as a confounding effect did not affect the significance of
the markers. After correction for the confounder effects (Model 3)
the inflation factor was reduced to l=1.17 and this was not
reduced by adding three additional MDS dimensions which
altogether captured an extra 5% of the genetic variance in the
markers (Table S2).
We examined candidate loci previously reported to have
associations with host response to Leishmania infection and
susceptibility to leishmaniasis in Homo sapiens (49 loci) and Mus
musculus (33 loci) to test in a systematic way if any of these loci
showed a stronger association in our canine dataset. When
possible, these were mapped to their orthologues in the dog
genome, and this was successful for 78 loci (95%; Dataset S1).
We selected SNPs in the GWAS data contained within these
candidate loci and their flanking regions (61 Mb) and assigned
them to sets of non-overlapping candidate regions. This resulted in
4,751 SNPs in 37 sets with a median of 108 SNPs (Dataset S1).
Sets were tested one at a time for association with the phenotype
controlling for within-set linkage disequilibrium (LD) and multiple
testing arising from the number of SNPs in the set as described
elsewhere [48] (r
2=0.80 and p=0.05 were used). Three sets of
SNPs on CFA 4, and one each on CFA 9 and 10 showed an
empirical set-specific p-value (EMP1),0.05 (Dataset S1). The
same sets showed EMP1,0.01 when r
2=0.10 and p=0.01 were
applied (see Materials and Methods). Although EMP1 does
not account for the fact that multiple sets are tested, the sets on
CFA 4 showed EMP1 values notably lower than for other sets
(Figure S3). The sets on CFA 4 spanned the region 61.2–
76.9 Mb which had previously showed the strongest associations
in the initial GWAS (Table S1). All the sets contain loci associated
with Leishmania infection, and the three sets on CFA 4 included
several genes (Il7r, Lifr, C6, C7 and Csf1r) that lie within a locus
involved in lesion development in murine Leishmania major infection
[49,50,51,52].
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genomic selection with the BayesB method [47] with some
modifications previously published [53]. Briefly, the BayesB
method first proposed by Meuwissen et al. [47] is a Bayesian
model in which the effect of SNPs on the total genetic values are
predicted simultaneously, with an a priori assumption that only few
SNPs are useful for predicting the trait. With the modified BayesB
method we used (from now onwards referred just as BayesB for
simplicity), Models 1–3 produced a similar genome-wide plot of
both estimated marker effects (Figure S4) and the proportion of
realisations a given marker was estimated to have a non-zero effect
(data not shown), with a most detectable peak on CFA 4:61–
77 Mb. This region overlapped with both the strongest association
in GWAS and the region in which SNP sets covering candidate
genes were significant (EMP1,0.01).
Estimating genetic variance in the phenotype
GWAS methodology is concerned with identifying individual
SNPs that may be a causative variant for the phenotype or in LD
with such a variant. Despite the failure to detect any such SNP, it
was possible to detect genetic variation relating to the leishman-
iasis phenotype. Two different approaches were adopted, the first
using a modified BayesB methodology [53] and the second a
Restricted Maximum Likelihood (REML) methodology imple-
mented within the GCTA package [54]. The estimates of
heritability obtained were 0.64 and 0.58 (s.e. 0.17) from BayesB
and GCTA, respectively (Table 1). These estimates were
corrected for genetic stratification (C1, C2) and lifestyle. Note
that these estimates are likely to be biased upwards because of the
selection of the samples contributing to the study – as would be
expected in a case-control study. Given the uncertainty of the
actual prevalence of the disease we decided to explore this using
GCTA by varying the prevalence from 0.01 to 0.6. As show in
Table S3, in all cases heritability was found notably greater than
zero and it went down to 0.32 with prevalence equal to 0.01.
Using BayesB the fraction of markers contributing to the genetic
variance was estimated as 0.015 (s.e. 0.011), however experience
with such methods suggests that this fraction is sensitive to the
distribution of allele effects that is assumed (results not shown). The
inclusion of an additional MDS dimension (C3) did not change the
results compared with Model 3.
Prediction of the phenotype
Cross-validation was used to test the predictive potential of
genomic evaluation. Five cross-validation sets (denoted A–E) were
produced at random from the full dataset to estimate the
predictive benefit when new individuals, which have not been
used to estimate the effects of markers and covariates, are
genotyped in order to predict their phenotypes. Two approaches
to assess the predictive value were adopted: the accuracy to predict
the phenotype and the capability to diagnose individuals from
genomic information.
Accuracy. The correlation between predicted fitted values for
the new individuals and their known actual phenotype was
calculated as a measure of accuracy (r) for predicting the
phenotype. The Model 1 results suggest that the combined SNP
effects predict the phenotype with an accuracy of 0.18 and that, by
comparison with Model 2, little accuracy is added by including
covariates correcting for genetic stratification (Table 2 and
Table 3). Including lifestyle, which was identified as a risk factor
in previous analyses, improved the accuracy to 0.29 (Table 4).
Still, the key question is whether the genomic data adds accuracy
and this was assessed in different ways.
Firstly, cross-validation was performed on permuted data prior
to the running of the BayesB analyses, where genotypes were
randomized with respect to both phenotypes and covariates, whilst
the link between phenotypes and covariates was maintained. In
general, accuracy values were notably lower with permuted data
than with the actual data, regardless of which of Models 1 to 3
were fitted. Within-set accuracies from permuted data were very
close to zero when no covariates (Model 1) and genetic
stratification (Model 2) were included. Statistical significance was
observed only when lifestyle was included (Model 3), which
confirms the earlier result that lifestyle has predictive value.
Secondly, to test the contribution of the genomic data, the
predictions obtained from the BayesB analysis were decomposed
into the component from the covariates and the component from
the SNPs. The SNP component was then permuted within the
cross-validation set as described in the Materials and Methods,
but maintaining the link between the predictor from covariates
and the phenotypes. For each permutation the accuracy of
prediction was calculated. Tables 2, 3, 4 show that the accuracy
from the observed data with the true link between phenotypes and
genotypes was in the upper tail of the distribution of accuracies
(P,0.05). Collectively this demonstrates the Models have
significant predictive value and that, within the predictor, the
genomic data makes a significant contribution to the accuracy.
Finally, the magnitude of the benefit from the genomic data was
assessed by predictions that excluded all genomic data. Overall
accuracy obtained by C1 and C2 as explanatory factors alone was
not significant (Table 3). Accuracy using only covariates in Model
3 was significant although the accuracy achieved was only half the
value obtained from the full Model (Table 4). Altogether, these
three ways to look at the data proved that prediction of the
phenotype was more accurate when genetic markers were
included.
Nevertheless, as may be expected from the relatively small data
sets, there is considerable variation among the cross validation sets,
and confidence intervals within individual cross-validation sets are
large. Predictive accuracies were significant in sets C and D, but
were not significant in sets A, B and E (Table 2), coinciding with a
slightly higher posterior fraction of markers with a non-zero (1–p)
effect for sets A, B and E than for C and D (data not shown).
Overall, there was an improvement in prediction by using SNPs.
Prediction of the trait. Our second approach to assess the
capability of our data to be used for prognosis of disease
development required individuals to be classified as either
healthy infected or affected for increasing thresholds of fitted
values. Note that the phenotype was defined as one or two for
Table 1. Summary results from the BayesB and GCTA
analyses.
Model 1 Model 2 Model 3 Model 4
BayesB
Posterior 1–p (%) 1.65 1.57 1.54 1.57
h
2 0.61 0.63 0.64 0.65
GCTA
h
2 (s.e.) 0.53 (0.18) 0.55 (0.18) 0.58 (0.17) 0.59 (0.17)
The estimates for the percentage of markers affecting the phenotype (1–p)a n d
its heritability (h
2) are shown for the different statistical models: Model 1
included no covariates; Model 2 included the first two dimensions of the MDS
analysis; Model 3 included the first two dimensions of the MDS analysis plus the
lifestyle; Model 4 included an additional dimension of the MDS analysis to
Model 3.
doi:10.1371/journal.pone.0035349.t001
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values were approximately in this range. Receiver operating
characteristic (ROC) curves were generated from sensitivity and
specificity values for different thresholds and the area under the
curve (AUC) was calculated as an indicative of the balance
between sensitivity and specificity. AUC values were notably
higher than randomness and Model 3 achieved the best
performance (Figure 1). Regardless of the model, a threshold of
1.5 to diagnose individuals would reach the highest fraction of
correct predictions (g), notably higher than the expected by chance
alone (for Model 3, g1.5=0.63; g95%limit=0.55) (Figure 2).
Discussion
In this study we have explored the contribution of genetic loci in
the dog genome for determining clinical progression of disease
following Leishmania infection and how such information may be
used to predict disease course. Our first analysis was focused on
identifying individual loci in the canine genome which contributed
medium to large effects for determining disease development.
Different analyses associated CFA 4: 61–77 Mb. The strongest
association in the GWAS analysis was for markers in this region,
even when we considered confounding factors such as lifestyle and
genetic stratification, whose causes are discussed below. However,
these associations were not significant when corrected for multiple
testing (Figure S1, Table S1). The lack of genome-wide
significance at the individual SNP level may indicate that our
study was underpowered for GWAS due to the small sample size
of our study. However the size of the study was at the lower end of
the range of 100–300 cases and 100–300 controls that has been
suggested for GWAS in dogs in complex diseases [33]. The lack of
genome-wide significance may also be evidence of a complex
genetic nature for leishmaniasis. This provides justification for the
genomic selection approach which is more suited to prediction of
complex traits (e.g. [47]).
Table 2. Summary of cross-validation results after constructing five sets (labelled A–E), showing the predictive accuracy when the
set is excluded from the training set for Model 1.
Model 1
Set A B C D E A–E
Ntraining 175 175 177 176 173
Ncases 21 21 20 20 22 104
Full model
Accuracy (r) 0.02 0.09 0.41 0.49 0.07 0.18
(95% CI) (20.28, 0.32) (20.21, 0.38) (0.13, 0.64) (0.22, 0.69) (20.23, 0.35) (0.05, 0.30)
Empirical significance 0.42 0.34 ,0.01 ,0.01 0.44 ,0.01
Permuted genotypes
Accuracy (r) 20.11 20.05 20.17 20.23 20.13 20.14
(95% CI) (20.39, 0.19) (20.34, 0.25) (20.45, 0.14) (20.49, 0.08) (20.41, 0.16) (20.27, 20.01)
Empirical significance was obtained from the fraction of permutations that showed a correlation higher than in the real data.
doi:10.1371/journal.pone.0035349.t002
Table 3. Summary of cross-validation results after constructing five sets (labelled A–E), showing the predictive accuracy when the
set is excluded from the training set for Model 2.
Model 2
Set A B C D E A–E
Ntraining 175 175 177 176 173
Ncases 21 21 20 20 22 104
Full model
Accuracy (r) 0.05 0.05 0.41 0.53 0.12 0.20
(95% CI) (20.26, 0.34) (20.25, 0.34) (0.12, 0.64) (0.27, 0.71) (20.18, 0.39) (0.07, 0.32)
Empirical significance 0.37 0.27 0.02 0.03 0.34 0.04
Permuted genotypes
Accuracy (r) 20.03 20.09 0.09 0.11 0.07 0.02
(95% CI) (20.32, 0.27) (20.38, 0.21) (20.22, 0.38) (20.20, 0.40) (20.23, 0.35) (20.11, 0.15)
Covariates alone
Accuracy (r) 0.003 20.06 0.23 0.43 0.17 0.11
(95% CI) (20.29, 0.30) (20.35, 0.24) (20.08, 0.50) (0.15, 0.65) (20.13, 0.43) (20.02, 0.24)
Empirical significance was obtained from the fraction of permutations that showed a correlation higher than in the real data.
doi:10.1371/journal.pone.0035349.t003
Genetic Control of Canine Leishmaniasis
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35349Interestingly, when we tested for association focusing only on
SNPs residing within candidate loci related to host response to
Leishmania and susceptibility to leishmaniasis in humans and mice
[50,55,56], loci on chromosome 4: 61–77 Mb were significant
after correcting for multiple testing and linkage disequilibrium
(Dataset S1 and Figure S3).
In addition, from the BayesB analysis, markers in this region of
CFA 4 had a larger estimated effect on the phenotype than other
genome-wide markers (Figure S4). Chromosome 4: 61–77 Mb is
syntenic to a locus that mediates host response to Leishmania major
in mice, which includes the candidate genes Il7r, Lifr, C6 and C7
[50]. Il7r (CFA 4: 75.8 Mb) is of special interest as, although
healthy infected and affected samples showed similar MAF and
observed heterozygosity values along CFA 4: 61–77 Mb, in both
groups three SNPs (CFA 4: 75.7–75.9 Mb) flanking Il7r
significantly deviated from HWE (p-value,10
25) (data not
shown). Extended patterns of markers deviating from HWE may
indicate copy number variants. Variation in the number of copies
between affected and healthy infected cannot be detected through
differences in genotype frequencies though it might affect the
phenotype. In fact, structural variations have been described for
the syntenic region in the human genome [57,55,58], which
encompasses SPEF2, CAPSL, UGT3A1 and UGT3A2 in addition to
Table 4. Summary of cross-validation results after constructing five sets (labelled A–E), showing the predictive accuracy when the
set is excluded from the training set for Model 3.
Model 3
Set A B C D E A–E
Ntraining 175 175 177 176 173
Ncases 21 21 20 20 22 104
Full model
Accuracy (r) 0.10 0.14 0.46 0.56 0.23 0.29
(95% CI) (20.20, 0.38) (20.16, 0.42) (0.18, 0.67) (0.32, 0.74) (20.06, 0.49) (0.16, 0.41)
Empirical significance 0.48 0.24 0.02 0.01 0.46 0.03
Permuted genotypes
Accuracy (r) 0.09 20.01 0.28 0.29 0.26 0.15
(95% CI) (20.22, 0.37) (20.31, 0.29) (20.03, 0.54) (20.01, 0.54) (20.03, 0.51) (0.02, 0.28)
Covariates alone
Accuracy (r) 0.11 0.03 0.35 0.43 0.34 0.22
(95% CI) (20.19, 0.40) (20.27, 0.32) (0.05, 0.59) (0.15, 0.65) (0.05, 0.57) (0.09, 0.35)
Empirical significance was obtained from the fraction of permutations that showed a correlation higher than in the real data.
doi:10.1371/journal.pone.0035349.t004
Figure 1. Receiver Operating Characteristic (ROC) curves.
Sensitivity and specificity values were obtained for increasing classifi-
cation thresholds to produce the ROC curves. In the legend, the values
for the area under the ROC curve (AUC) are indicated in parenthesis for
each model. AUC can range between 0.5 (randomness, dashed line) and
1.0 (ideally).
doi:10.1371/journal.pone.0035349.g001
Figure 2. Fraction of correct predictions. For increasing classifica-
tion thresholds percentages of correct classifications were compared to
those expected by chance. Calculations for the random expectation and
the random 95% limit were drawn from a hypergeometric distribution
and are detailed in Text S1.
doi:10.1371/journal.pone.0035349.g002
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shorter region overlapping Ugt3a1 [59]. However, replication in an
independent sample is needed to confirm the association on
chromosome 4, as well as those on chromosomes 1 and 20, and the
identification of these regions only represents a first discovery step
for a better understanding of the genetic variants that control
genetic susceptibility to clinical progression of leishmaniasis from
Leishmania infection.
Next, we studied the extent to which the additive effects of loci
throughout the genome determine the disease development
following Leishmania infection. Our data suggest that the trait is
complex with many different gene segments contributing to the
phenotype and that the genetic variance may explain as much as
60% of the total observed phenotypic variance. Whilst this
estimate was fairly consistent across the different methodologies
used for its estimation (Table 1), the estimation is made more
complex and very likely to be biased upward, by the case-control
nature of the data. This is the first clear evidence that there is a
significant genetic component to leishmaniasis in dogs within
breeds. In addition, it is the first heritability estimate for
progression of clinical leishmaniasis from Leishmania infection in
any species, although an estimate of heritability for a marker of
healed Leishmania infection and protection against subsequent
reinfection in humans has been reported [19].
An important finding of this study was that whilst no single SNP
was found to be reliably predictive, there was significant predictive
value of the genomic data through using the genomic evaluation as
proposed by Meuwissen et al. [47]. The best predictor included
information on lifestyle as well as the genomic predictor, but it was
clearly established that the genomics made a substantial
contribution to the accuracy. The model including the covariates
and the genomic data reached an accuracy of 0.29 for a dog that
was outside the current dataset (e.g. a newborn dog), and thus is
only weakly predictive of the phenotype. However three points
should be remembered. Firstly this accuracy was achieved using
80% of the data (the other 20% were used for cross-validation),
and that the total data consisted of only 219 infected animals, of
which only 104 had developed the disease. Secondly, this accuracy
is the prediction of a phenotype and not the underlying genetic
liability, and the accuracy of predicting the genetic liability is likely
to be greater. In random sample with continuous traits the
accuracy would be scaled by 1/h (.1) where h is the square root
of the heritability. The structure of the data prevents us from
proposing any correction. Thirdly the value of using genomics is
that the genomic data can be accumulated over time with
increasing accuracy of prediction. One might anticipate that
further collection of cases and controls would increase accuracy to
levels that have the potential for making a clinical impact on
breeding for resistance away from the development of pathology,
i.e. toleration of the parasite.
Finally, we would like to comment on the possible causes of the
genetic stratification seen in our dataset, which especially affected
the GWAS results and could only be reduced to l=1.17, and to
compare with other GWAS in dogs. Roughly half of the dozen
published GWAS in dogs provided information with regard to
stratification. Three studies [37,45,43] observed good clustering of
cases and controls when plotting the first two MDS dimensions, in
spite of different geographical origin of the samples in the study
from Madsen et al.. Barber et al. [42] also used MDS in order to
detect stratification and excluded a good number of outlier
samples. Wilbe et al. [34] and Downs et al. [60] reported inflation
factor values, before correction, of 1.3 and 1.4, respectively. Both
studies observed clustering of either samples with similar
geographic provenance [34] or known to be related [60] and
performed a Cochran-Mantel-Haenszel stratified analysis within
the clusters as a measure of correction. However, no value of the
inflation factor after the correction was presented. Only Olsson
and collegues reported an inflation factor of 1.2 after removing
two outliers in the MDS plot [35]. We consider that it is unlikely
that our lambda value was inflated due to population stratification
because we neither observed geographical clustering of samples
within Spain (the majority of the samples were collected from
different areas in the country) nor differentiation of samples
collected in other countries (i.e. Italy, Greece and Portugal). It is
reasonable to think that geographical stratification would have
been noticed if present, as it has happened with some other canine
GWAS. Although population or geographical stratification is a
common cause of increased inflation factor, there are other
confounder effects that can produce the same results [61]. We
tried to avoid differential bias by following the same procedures in
the collection of samples and clustering of samples that went
through different DNA extraction protocols or genotyping batches
was ruled out. Although we tried to avoid family structure by not
including members of the same family, cryptic relatedness might
have certainly inflated the lambda value. Nonetheless, we note that
lambda values .1.05 are typically considered to denote
stratification in human studies [61]. Although this is a statistical
rule-of-thumb and it should be the same regardless of the species,
we wonder if certain relatedness owing to founder effects,
inbreeding, popular sire effects and repeated mating might be
inherent to GWAS in dogs in spite of a careful study design.
Materials and Methods
Ethics statement
The dogs in the study were examined during routinary
veterinary procedures by the veterinary clinics participating in
the study. All samples were collected for routine diagnostic and
clinical purposes. The samples were obtained during veterinary
procedures that would have been carried out anyway and DNA
was extracted from residual surplus of samples and used in the
study with verbal owner consent. This is a very special situation in
veterinary medicine. As the data are from client-owned dogs that
underwent normal veterinary exams, there was no ‘‘animal
experiment’’ according to the legal definitions in Spain and the
United Kingdom, and approval by an ethical committee was not
necessary.
Study population and epidemiology
The study population consisted of a single breed of dogs (Boxer).
This design was chosen as the use of a single breed for the first
stage of GWAS in dogs will increase power by reducing effects of
genetic differentiation between breeds and increasing the degree of
linkage disequilibrium [33]. Moreover, this breed appears more
predisposed to overt CanL than others [23,62,63] . An age
criterion for study inclusion was applied (see below) as it has been
reported that age distribution of the prevalence of infection follows
a bimodal pattern, with the first peak including dogs diagnosed at
2 to 4 years of age and the second peak including dogs about 7
years old [64]. The study was carried out in collaboration with the
Hospital Clı ´nic Veterinari of the Universitat Auto `noma de
Barcelona (HCV-UAB) and therefore most Boxers included were
from the metropolitan area of Barcelona, Spain, where the HCV-
UAB is located. A number of Boxers from other areas where the
disease is endemic were also included (Spain, Greece, Italy and
Portugal).
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Veterinary clinics and dog owners were encouraged to
participate in the study, in the case of the latter through their
veterinary centre. Two millilitres of EDTA peripheral blood and
2 ml of serum were required. In addition, other tissues (e.g. bone
marrow) as well as conjunctiva or lesion swabs were received
occasionally. With regard to CanL, no pre-screening of the
samples sent to the laboratory was done by the veterinary clinics.
Dogs affected by CanL included those with a documented history
of disease, undergoing a relapse or newly diagnosed. For those
showing a disease episode when samples were collected, additional
samples were requested one month after treatment or if requested
by the referring clinician in order to both confirm the diagnosis
and help inform then clinician on treatment response. For healthy
infected dogs (see below), additional samples and medical
information were requested to confirm the absence of CanL
development. Inclusion of additional samples relied on the
collaboration of veterinary clinics.
Phenotype definition, clinical classification and
laboratory tests
Dogs were classified by clinical signs, clinical biochemistry,
direct parasite detection and anti-Leishmania immune reactions into
the following groups: (i) healthy infected: healthy and .4 years old
but with evidence of prior infection and (ii) affected: manifest
clinical disease and diagnosed before the age of 4 years. Ages were
recorded as age-of-onset of disease for affected and current age at
sample collection for healthy infected dogs. Lifestyle (i.e. living
indoors, outdoors, both or undetermined), gender, level of
relatedness and geographic location of origin were also collected.
Leishmania quantitative polymerase chain reaction (qPCR) and
anti-Leishmania Enzyme-Linked ImmunoSorbent Assay (ELISA)
were performed on all samples from all dogs, although additional
results from direct parasite detection and anti-Leishmania immune
tests were provided by veterinary clinics for most samples.
Leishmania qPCR was performed at the Servei Veterinari de
Gene `tica Molecular, UAB, as described previously [62] and
ELISA was performed at UNIVET Servicio de Diagno ´stico
Veterinario SL, UAB, as described elsewhere [63].
DNA extraction, SNP genotyping and data quality control
DNA was extracted from peripheral blood and bone marrow
samples using either QIAampH DNA Blood Mini Kit (QIAGEN)
or by conventional phenol-chloroform DNA extraction and
deproteinization methods. All samples were genotyped using the
Illumina CanineHD BeadChip (174,376 markers) [65] at the
Centre National de Ge ´notypage, France. Data cleaning was
conducted using PLINK [48] and R version 2.13.0 [66] packages.
Quality control was performed independently on two genotyping
batches. In total eight samples with call rate ,90% were excluded.
Intensity probes were excluded together with markers on the
boundary autosomal region on the CFA X and SNPs on the non-
pseudoautosomal region on CFA X for which heterozygous
genotypes in male samples were observed. Markers with call rate
,90% were also excluded. Multidimensional scaling (MDS)
analysis based on the genotypes was performed to detect samples
with a very different genetic content (explained below). Three
affected dogs were excluded because they appeared as outliers
when the first two dimensions from the MDS analysis were plot
(data not shown). After data cleaning 115 healthy infected and 104
affected dogs remained. In addition, markers were filtered to have
a minor allele frequency (MAF) .1.5% and a Hardy-Weinberg
Equilibrium (HWE) test p-value.0.005 (a threshold set based on
the empirical distribution of our data). This left 126,607 markers
for analysis. Finally, for logistic regression and BayesB analyses,
one SNP of a pair was removed for those SNP pairs showing
complete genotypic correlation, resulting in 99,997 SNPs left for
analysis.
Statistical analysis
Covariates. Two confounding effects were considered and
fitted into the statistical analyses: genetic stratification and dog
lifestyle. Using PLINK [48], an identical-by-state correlation
matrix for n individuals was calculated from which n dimensions
were extracted using MDS analysis, resulting in a matrix of n-
samples by n-dimensions eigenvalues. The fraction of genetic
variance explained by each dimension was calculated as the
variance for a given dimension along all samples divided by the
sum of variances for all the dimensions extracted. The eigenvalues
for the first two dimensions (C1 and C2) of the MDS analysis were
used as continuous covariates. For simplicity, only C1 and C2
were used because the fraction of additional genetic variance
explained by each of the subsequent 217 MDS dimensions
extracted was minimal (Figure S2). Although healthy infected
and affected samples generally clustered together in the MDS plot
(Figure S2), genetic stratification was observed in our cleaned
dataset based on the genomic inflation factor (l=1.29), with C1
capturing twice the stratification captured by C2. Therefore, C1
and C2 values for each sample were fitted as continuous covariates
in the indicated models. CanL is known to be a complex disease
with an environmental component and thus dogs living outdoors,
more exposed to infection, are believed to more frequently develop
the disease. Hence, lifestyle was also included as a factor in the
analyses for the models indicated. For Model 3, the inflation factor
was reduced to l=1.17. In the logistic regression, lifestyle was
fitted as a factor (one degree of freedom) using dummy variables
for indoors, indoors/outdoors, outdoors and ‘undetermined’. In
the genomic selection analyses, lifestyle was considered as a
categorical covariate with four levels. Three genetic models
varying in whether covariates were fitted were defined to explain
the phenotype (y), treated as binary (i.e. either healthy infected or
affected):
Model 1: y,SNPs
Model 2: y,SNPs+C1+C2
Model 3: y,SNPs+C1+C2+lifestyle
GWAS and candidate genes analysis
Markers were tested for association using the Cochran-
Armitage for trend test (Model 1) and logistic regression (Models
2 and 3). Genome-wide significance (Pgenome) was obtained after
10,000 permutations. Based on the permutations carried out in
our dataset, the uncorrected p-value that would reach genome-
wide significance (at the 5% level) after correction for multiple
testing in our study would be p=2.08610
26. Formally, first, for
each permutation the maximum statistic across all SNPs was
recorded and, second, from this distribution of maximum statistics,
the statistic in the top 5% is used to give the p=2.08610
26 that
would be significant after permutations.
Candidate loci reported as related to host response to Leishmania
and susceptibility to leishmaniasis in Mus musculus and Homo sapiens
[56,67] were used to retrieve homologous loci in C. familiaris using
Biomart [68] with CanFam 2.0. Sets were defined with SNPs in
the Illumina’s CanineHD Beadchip residing within the retrieved
candidate loci and their flanking regions (61 Mb). Loci for which
at least one SNP overlapped were merged into the same set
(Dataset 1). Set-based association tests were performed as
described in PLINK [53] with two different sets of parameters:
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2=0.80, p-value=0.05; and (2) r
2=0.10, p-value=0.01. In
both cases, a maximum set size of 10 SNPs (,10% of the median
set size) was used. The Cochran-Armitage for trend test was used
and 10,000 within-set permutations were conducted to obtain
empirical set-based p-values (EMP1).
Modified BayesB method. Datasets were analysed with the
BayesB method [47] with some modifications previously published
[53] assuming Models 1–3. The phenotype was treated as
continuous. A flat prior distribution for the proportion of markers
with non-zero additive effect (1–p) was set to follow a beta
distribution with parameters a=1 and b=1 and a starting value of
0.2. An informative distribution for the variance for the additive
parameter was set to follow an inverse chi-squared distribution with
two degrees of freedom (n=2) and a scale parameter (S) of 0.001
(weak prior). The Markov chain Monte Carlo (MCMC) of BayesB
wasrun for160,000cyclesand the first10,000cycleswerediscarded
as burn in; 3,000 realisations of sampling were performed with 50
cycles between realisations. Absolute variation between each of the
3,000 sampled values of posterior S and their prior S (either
S=0.001 or S=0.1) was calculated and a Welch two sample t-test
was applied. The same test was applied to the sampled values of (1–
p) produced by each of weak and stronger S priors. BayesB
produced estimates of the genomic breeding values (GEBV) and of
the effects of C1, C2 and each lifestyle category, which were used to
calculate fitted values of the phenotype (y ˆ) according to the different
predictive models (Text S1).
In order to assess the effect of the weak informative prior
distribution used for the variance of the additive parameter on the
resulting posterior value, for Model 1 the analysis was repeated
with S=0.1 (strong prior), which was 100 times higher than the
value used otherwise. In absolute values, the posterior S value
changed a 58.7% respect to the weak prior (S=0.001) whereas this
variation was significantly greater, 78.9%, for S=0.1 (p-
value=7610
26). Another effect of giving a stronger prior S was
that the posterior proportion of markers with a non-zero effect (1–
p) was 100 times lower compared to the obtained for the weak
prior (0.02% and 1.65%, respectively, p-value=2610
216) and the
fraction of genetic variance was also lower (0.27 and 0.61,
respectively). Moreover, the genome-wide pattern of estimated
SNP effects was notably different depending on the prior given.
With a weak prior most markers had non-zero but very low
estimated effect (10%-quantile=10
25) whereas a small fraction of
SNPs (10%-quantile=0) had 10-fold estimated effects with a
stronger prior. Altogether these results can be explained by a
scenario in which fewer SNPs with greater effect contribute to the
phenotype when a greater prior variance of the additive parameter
is allowed.
Restricted Maximum Likelihood (REML) analysis (GCTA
software). When calculating the genetic relationship matrix
(GRM) with GCTA [54], no adjustment was specified to correct
for imperfect LD between genotyped markers and causal loci.
REML analyses were run assuming Models 1–3. As input
parameters, genetic and environmental variances were not
specified and default values of 0.12 for both were used. Model 3
was run with varying phenotype prevalence values from 0.01 to
0.60 in order to explore the sensitivity of estimates to prevalence.
Cross-validation. Samples were assigned randomly to one of
five training sets (denoted A–E) so that (i) each training set had a
size of approximately 4/5 of the full unpermuted dataset and (ii) in
each training set the proportions of samples belonging to each
phenotype (either affected or healthy infected) and lifestyle
categories were approximately as in the full dataset. Samples not
included in each training set were used as testing data. For each
training set, BayesB was run to both estimate EC1,E C2,E life from
samples in the training set and produce GEBV for the testing data
samples and then calculate their fitted values, according to the
corresponding predictive model.
Accuracy (r) was calculated as the correlation between fitted
values (y ˆ) and true phenotypes (y). In each testing set, r was
calculated as a measure of accuracy to predict the phenotype. The
overall correlation for the full unpermuted dataset was calculated
by combining the predictions across sets. The contribution of
markers to the accuracy was analysed in three ways. First, GEBV
generated with BayesB were permuted before the calculation of
fitted values. In this way, the correspondence between phenotypes
and covariates was not altered. Within each model, 100 sets of
permuted GEBV, resulting in 100 sets of permuted fitted values,
were generated for each set. The empirical p-value for the real
data was computed as the fraction of permuted sets with a lower p-
value that the real data. Second, genotypes were randomized
respective to phenotypes and covariates, which were kept as in the
original data. The BayesB analysis was then run and cross-
validation applied as explained before. Third, fitted values were
calculated using uniquely covariates, i.e. GEBV were not used.
For Models 1–3, receiver operating characteristic (ROC) curves
were calculated as follows. A fitted value threshold was set so that
below or above it individuals were predicted to be healthy infected
or affected, respectively. Specificity, sensitivity and fraction of
correct predictions (g) values were calculated (Text S1) for
increasing thresholds of fitted values and ROC curves were
generated by plotting specificity against sensitivity. The area under
the ROC curve (AUC) was calculated as a measure of similarity
between specificity and sensitivity.
Supporting Information
Figure S1 Single-marker genome-wide association plot
for Model 1 after 10,000 permutations with the strongest
associations indicated.
(TIFF)
Figure S2 Genetic stratification. (A) relative genetic vari-
ance explained by the 219 MDS dimensions extracted; (B) MDS
plot for the first two MDS dimensions (C1 and C2) with healthy
infected and affected samples coloured differently. The percentage
of relative genetic variance explained by each dimension is
indicated as well as the genomic inflation factor (lambda).
(TIFF)
Figure S3 Distribution of EMP1 across SNP sets of
candidate regions. Sets comprise SNPs in the following regions:
6 (CFA 4:61.2–63.2 Mb), 7 (CFA 4: 70.5–74.5 Mb), 8 (CFA 4:
74.8–76.9 Mb), 19 (CFA 9: 40.0–46.5 Mb) and 22 (CFA 10: 29.6–
31.5 Mb).
(TIFF)
Figure S4 Genome-wide plot of the absolute mean SNP
effects estimated with BayesB for Model 1 (A), Model 2
(B) and Model 3 (C). The peak on CFA 4: 61–77 Mb (red
segment) consistent across Models 1–3 coincided with both the
strongest association in GWAS analysis and the region in which
SNP sets covering candidate genes were significant (EMP1,0.01).
(TIFF)
Table S1 Strongest associations from each region
identified in the GWAS analysis. BICF2P1345879 was not
used in models 2 and 3 because, for logistic regression, SNPs were
pruned based on LD (see Materials and Methods).The closest
marker, ,6 Kb upstream, was BICF2P813758 at 20:30,126,
633 bp (Model 2: Praw=4.4610
24,P genome.0.50, OR=0.33;
Model 3: Praw=6.2610
24,P genome.0.50, OR=0.34). Choice of
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strongest associations in Model 1. Canis familiaris genes (Can-
Fam_2.0) were retrieved using Biomart and associated gene names
are given, with the exception of some for which no gene name was
available and the Ensembl ID is given instead. The same
information is presented for the strongest associations on
chromosomes 9 and 10 from the set-based analysis.
(XLS)
Table S2 Genomic inflation (l) was not affected by
fitting additional MDS dimensions as covariates of the
model.
(DOC)
Table S3 Sensitivity of heritability (h
2) estimation using
GCTA to prevalence of the phenotype is shown for Model
3.
(DOC)
Text S1 Fitted values, fraction of correct predictions,
sensitivity and specificity calculation.
(DOC)
Dataset S1 Candidate genes analysis: (A) candidate
genes and loci described in H. sapiens and M. musculus
and retrieved genomic positions in C. familiaris; (B) sets
of non-overlapping candidate regions plus their ±1 Mb-
flanking regions; (C) results from the set-based associ-
ation study.
(XLS)
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